[Clinical study of a new, normophasic type oral contraceptive].
D001940:Breast / Q000187:drug effects; D003276:Contraceptives, Oral / Q000009:adverse effects / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007866:Leg / Q000098:blood supply; D007973:Leukorrhea / Q000139:chemically induced; D007989:Libido / Q000187:drug effects; D008234:Lynestrenol / Q000009:adverse effects / Q000494:pharmacology*; D008598:Menstruation / Q000187:drug effects; D008796:Metrorrhagia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D013997:Time Factors; D014652:Vascular Diseases / Q000139:chemically induced
D003276:Contraceptives, Oral; D004997:Ethinyl Estradiol; D008234:Lynestrenol
Etude clinique d'un nouveau contraceptif oral de type normophasique.